24th Apr 2015 16:54
Holdings in Company
Burton-on-Trent, UK - 24 April 2015 - Clinigen Group plc ('Clinigen' or the 'Company', AIM: CLIN), the specialty global pharmaceutical company, announces that it was informed today that Andrew Derrick Leaver today sold a total of 3,000,000 ordinary shares of 0.1 pence each in the Company. Following this transaction Mr Leaver is interested in a total of 14,098,565 ordinary shares in Clinigen representing 17.1 per cent. of the Company's issued share capital, and combined Mr and Mrs Leaver are interested in a total of 16,430,425 ordinary shares in Clinigen representing 19.9 per cent. of the Company's issued share capital.
Contact Details
Instinctif Partners - Media Relations | Tel: +44 (0) 20 7457 2020 |
Melanie Toyne-Sewell/Jen Lewis/Emma Barlow | Email: [email protected] |
About Clinigen Group
The Clinigen Group is a specialty global pharmaceutical company headquartered in the UK, with offices in the US and Japan. The Group, dedicated to delivering 'the right drug, to the right patient at the right time', has three operating businesses; Specialty Pharmaceuticals (SP), Clinical Trials Supply (CTS), and Global Access Programs (GAP). SP focuses on acquiring and in licensing specialist, hospital only medicines worldwide and commercializing them within niche markets. CTS sources commercial medical products for use in clinical studies only, including comparator drugs, adjuvant drugs and rescue therapies. GAP specializes in the consultancy, development, management and implementation of programs providing access for patients and their clinicians to drugs not available in their markets.
For more information, please visit www.clinigengroup.com.
Related Shares:
CLIN.L